Equities research analysts expect that Dextera Surgical Inc. (NASDAQ:DXTR) will post sales of $880,000.00 for the current quarter, Zacks reports. Two analysts have provided estimates for Dextera Surgical’s earnings, with the highest sales estimate coming in at $970,000.00 and the lowest estimate coming in at $790,000.00. Dextera Surgical reported sales of $800,000.00 during the same quarter last year, which would suggest a positive year over year growth rate of 10%. The firm is expected to report its next quarterly earnings report on Tuesday, February 6th.

On average, analysts expect that Dextera Surgical will report full year sales of $880,000.00 for the current year, with estimates ranging from $3.75 million to $3.87 million. For the next fiscal year, analysts expect that the company will report sales of $7.21 million per share. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Dextera Surgical.

Dextera Surgical (NASDAQ:DXTR) last announced its quarterly earnings data on Thursday, November 9th. The medical instruments supplier reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.02). The firm had revenue of $0.69 million during the quarter, compared to the consensus estimate of $0.62 million.

Several equities analysts recently commented on DXTR shares. Ladenburg Thalmann Financial Services started coverage on Dextera Surgical in a research report on Wednesday, August 16th. They set a “buy” rating and a $0.80 target price for the company. Zacks Investment Research downgraded Dextera Surgical from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th.

WARNING: “$880,000.00 in Sales Expected for Dextera Surgical Inc. (DXTR) This Quarter” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/11/21/880000-00-in-sales-expected-for-dextera-surgical-inc-dxtr-this-quarter.html.

Dextera Surgical (NASDAQ DXTR) opened at $0.15 on Tuesday. Dextera Surgical has a 52-week low of $0.11 and a 52-week high of $2.33.

Institutional investors and hedge funds have recently modified their holdings of the business. Perkins Capital Management Inc. bought a new position in Dextera Surgical in the 2nd quarter valued at $100,000. Virtu KCG Holdings LLC raised its position in shares of Dextera Surgical by 1,380.6% during the second quarter. Virtu KCG Holdings LLC now owns 369,918 shares of the medical instruments supplier’s stock worth $111,000 after acquiring an additional 344,933 shares during the last quarter. Finally, Broadfin Capital LLC raised its position in shares of Dextera Surgical by 64.7% during the second quarter. Broadfin Capital LLC now owns 987,520 shares of the medical instruments supplier’s stock worth $296,000 after acquiring an additional 388,080 shares during the last quarter. Hedge funds and other institutional investors own 6.06% of the company’s stock.

Dextera Surgical Company Profile

Dextera Surgical Inc, formerly Cardica, Inc, designs and manufactures stapling devices that enable the advancement of minimally invasive surgical procedures. The Company is engaged in commercializing and developing its MicroCutter 5/80 stapler based on its staple-on-a-strip technology for use by thoracic, pediatric, bariatric, colorectal and general surgeons.

Get a free copy of the Zacks research report on Dextera Surgical (DXTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dextera Surgical (NASDAQ:DXTR)

Receive News & Ratings for Dextera Surgical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dextera Surgical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.